Clinical Trials Browser

Not yet recruiting × Interventional × Letrozole × Clear all

NCT07389733 2026-03-02

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

Phase 1/2 Not yet recruiting

Advanced Unresectable or Metastatic Breast Cancer of Adults

NCT07394946 2026-02-20

NELOPHER

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07379502 2026-01-30

Endometrial Response in Polycystic Ovarian Syndrome Treated With Letrozole Alone or With Added Estradiol Valerate

Phase NA Not yet recruiting

Polycystic Ovary Syndrome

NCT07349069 2026-01-22

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07340658 2026-01-14

SIE-3

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07305246 2025-12-26

Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07101159 2025-08-03

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06810492 2025-03-17

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

Phase NA Not yet recruiting

Breast Neoplasms

NCT06405178 2024-05-08

Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome

Phase 3 Not yet recruiting

Polycystic Ovary Syndrome

NCT06405243 2024-05-08

Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients

Phase 3 Not yet recruiting

Polycystic Ovary Syndrome

NCT05979220 2023-08-07

Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy

Phase 2 Not yet recruiting

Breast Neoplasms

NCT04137640 2021-07-20

Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy

Phase 4 Not yet recruiting

Breast Neoplasms